Literature DB >> 23363829

Evaluation of an algorithmic approach in comparison with the Illumigene assay for laboratory diagnosis of Clostridium difficile infection.

A Walkty1, P R S Lagacé-Wiens, K Manickam, H Adam, P Pieroni, D Hoban, J A Karlowsky, M Alfa.   

Abstract

The following three diagnostic algorithms were evaluated in comparison with the Illumigene assay as a stand-alone test for Clostridium difficile detection: glutamate dehydrogenase antigen screen (GDH) followed by toxin A/B antigen testing (Tox A/B) with the cell cytotoxicity assay for discordant specimens (algorithm 1), GDH followed by the Illumigene (algorithm 2), and GDH followed by Tox A/B with the Illumigene for discordant specimens (algorithm 3). A total of 428 stool specimens submitted to three clinical microbiology laboratories in Manitoba, Canada, for C. difficile detection between June 2011 and April 2012 were included in the study. The prevalence of C. difficile in the stool specimens was 14.7% (63/428) based on toxigenic culture (microbiologic reference standard). The sensitivity and specificity of the Illumigene for C. difficile detection were 73.0% and 99.7%, respectively. The corresponding sensitivities and specificities were 65.1% and 100.0% for algorithm 1, 68.3% and 100.0% for algorithm 2, and 69.8% and 100.0% for algorithm 3. Using algorithm 1, a cell cytotoxicity assay was required for toxin detection in 37% of positive tests, prolonging turnaround time. However, the predictive value of a positive test based on a clinical reference standard (all tests positive or cytotoxigenic culture positive and clinical disease on chart review) was slightly higher with algorithm 1 than with the Illumigene assay as a stand-alone test or as part of an algorithm (algorithms 2 and 3). Based on a reduction in turnaround time, simplicity, and acceptable sensitivity and specificity, we recommend algorithm 2 (screening with the GDH antigen test and confirmatory testing with the Illumigene).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23363829      PMCID: PMC3666773          DOI: 10.1128/JCM.03203-12

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

1.  Rapid and sensitive loop-mediated isothermal amplification test for Clostridium difficile detection challenges cytotoxin B cell test and culture as gold standard.

Authors:  Torbjörn Norén; Ingegärd Alriksson; Josefin Andersson; Thomas Akerlund; Magnus Unemo
Journal:  J Clin Microbiol       Date:  2010-11-24       Impact factor: 5.948

2.  Detection of toxigenic Clostridium difficile: comparison of the cell culture neutralization, Xpert C. difficile, Xpert C. difficile/Epi, and Illumigene C. difficile assays.

Authors:  P Pancholi; C Kelly; M Raczkowski; J M Balada-Llasat
Journal:  J Clin Microbiol       Date:  2012-01-25       Impact factor: 5.948

3.  Evaluation of diagnostic tests for Clostridium difficile infection.

Authors:  Jonathan Swindells; Nigel Brenwald; Nathan Reading; Beryl Oppenheim
Journal:  J Clin Microbiol       Date:  2009-12-23       Impact factor: 5.948

4.  Evaluation of Clostridium difficile fecal load and limit of detection during a prospective comparison of two molecular tests, the illumigene C. difficile and Xpert C. difficile/Epi tests.

Authors:  Clare E Gyorke; Susan Wang; Jhansi L Leslie; Stuart H Cohen; Jay V Solnick; Christopher R Polage
Journal:  J Clin Microbiol       Date:  2012-10-10       Impact factor: 5.948

5.  Loop-mediated isothermal amplification compared to real-time PCR and enzyme immunoassay for toxigenic Clostridium difficile detection.

Authors:  Bobby L Boyanton; Preethi Sural; Caroline R Loomis; Christine Pesta; Laura Gonzalez-Krellwitz; Barbara Robinson-Dunn; Paul Riska
Journal:  J Clin Microbiol       Date:  2011-12-21       Impact factor: 5.948

6.  Impact of clinical symptoms on interpretation of diagnostic assays for Clostridium difficile infections.

Authors:  Erik R Dubberke; Zhuolin Han; Linda Bobo; Tiffany Hink; Brenda Lawrence; Susan Copper; Joan Hoppe-Bauer; Carey-Ann D Burnham; William Michael Dunne
Journal:  J Clin Microbiol       Date:  2011-06-22       Impact factor: 5.948

7.  Evaluation of a loop-mediated isothermal amplification assay for diagnosis of Clostridium difficile infections.

Authors:  Valérie Lalande; Laurence Barrault; Sophie Wadel; Catherine Eckert; Jean-Claude Petit; Frédéric Barbut
Journal:  J Clin Microbiol       Date:  2011-04-27       Impact factor: 5.948

8.  New selective medium for isolating Clostridium difficile from faeces.

Authors:  S T Aspinall; D N Hutchinson
Journal:  J Clin Pathol       Date:  1992-09       Impact factor: 3.411

Review 9.  Clostridium difficile-associated diarrhea in adults.

Authors:  Susan M Poutanen; Andrew E Simor
Journal:  CMAJ       Date:  2004-07-06       Impact factor: 8.262

10.  The diagnosis of Clostridium difficile-associated diarrhea: comparison of Triage C. difficile panel, EIA for Tox A/B and cytotoxin assays.

Authors:  M J Alfa; B Swan; B VanDekerkhove; P Pang; G K M Harding
Journal:  Diagn Microbiol Infect Dis       Date:  2002-08       Impact factor: 2.803

View more
  10 in total

1.  Molecular test based on isothermal helicase-dependent amplification for detection of the Clostridium difficile toxin A gene.

Authors:  Catherine Eckert; Eleonore Holscher; Amandine Petit; Valérie Lalande; Frédéric Barbut
Journal:  J Clin Microbiol       Date:  2014-04-23       Impact factor: 5.948

2.  Evaluation of a new automated homogeneous PCR assay, GenomEra C. difficile, for rapid detection of Toxigenic Clostridium difficile in fecal specimens.

Authors:  Jari J Hirvonen; Silja Mentula; Suvi-Sirkku Kaukoranta
Journal:  J Clin Microbiol       Date:  2013-06-26       Impact factor: 5.948

Review 3.  Laboratory Tests for the Diagnosis of Clostridium difficile.

Authors:  Karen C Carroll; Masako Mizusawa
Journal:  Clin Colon Rectal Surg       Date:  2020-02-25

4.  Comparison of BD Max Cdiff and GenomEra C. difficile molecular assays for detection of toxigenic Clostridium difficile from stools in conventional sample containers and in FecalSwabs.

Authors:  J J Hirvonen; S-S Kaukoranta
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-01-24       Impact factor: 3.267

5.  Time trends and predictors of laboratory-confirmed recurrent and severe Clostridioides difficile infections in Manitoba: a population-based study.

Authors:  Seth R Shaffer; Zoann Nugent; Andrew Walkty; B Nancy Yu; Lisa M Lix; Laura E Targownik; Charles N Bernstein; Harminder Singh
Journal:  CMAJ Open       Date:  2020-11-16

6.  Hospital discharge abstracts have limited accuracy in identifying occurrence of Clostridium difficile infections among hospitalized individuals with inflammatory bowel disease: A population-based study.

Authors:  Harminder Singh; Zoann Nugent; B Nancy Yu; Lisa M Lix; Laura Targownik; Charles Bernstein
Journal:  PLoS One       Date:  2017-02-15       Impact factor: 3.240

7.  A Laboratory Medicine Best Practices Systematic Review and Meta-analysis of Nucleic Acid Amplification Tests (NAATs) and Algorithms Including NAATs for the Diagnosis of Clostridioides (Clostridium) difficile in Adults.

Authors:  Colleen S Kraft; J Scott Parrott; Nancy E Cornish; Matthew L Rubinstein; Alice S Weissfeld; Peggy McNult; Irving Nachamkin; Romney M Humphries; Thomas J Kirn; Jennifer Dien Bard; Joseph D Lutgring; Jonathan C Gullett; Cassiana E Bittencourt; Susan Benson; April M Bobenchik; Robert L Sautter; Vickie Baselski; Michel C Atlas; Elizabeth M Marlowe; Nancy S Miller; Monika Fischer; Sandra S Richter; Peter Gilligan; James W Snyder
Journal:  Clin Microbiol Rev       Date:  2019-05-29       Impact factor: 26.132

8.  Direct cost of health care for individuals with community associated Clostridium difficile infections: A population-based cohort study.

Authors:  Harminder Singh; Zoann Nugent; A Walkty; B Nancy Yu; Lisa M Lix; Laura E Targownik; Charles N Bernstein; Julia Witt
Journal:  PLoS One       Date:  2019-11-08       Impact factor: 3.240

9.  Effect of clinical versus administrative data definitions on the epidemiology of C. difficile among hospitalized individuals with IBD: a population-based cohort study.

Authors:  Seth R Shaffer; Zoann Nugent; Charles N Bernstein; Andrew Walkty; Harminder Singh
Journal:  BMC Gastroenterol       Date:  2022-03-26       Impact factor: 3.067

10.  Evaluation of Xpert C. difficile, BD MAX Cdiff, IMDx C. difficile for Abbott m2000, and Illumigene C. difficile Assays for Direct Detection of Toxigenic Clostridium difficile in Stool Specimens.

Authors:  Bo-Moon Shin; Sun Mee Yoo; Won Chang Shin
Journal:  Ann Lab Med       Date:  2016-03       Impact factor: 3.464

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.